【スタッフ紹介】木浦 勝行

【卒業年】 1983年(昭和58年)

【学位取得年月】 平成 5年 9月

【専門領域】
内科学,呼吸器病学,胸部腫瘍学

【資格】
昭和58年 5月  医師免許取得
平成14年10月 社団法人日本呼吸器学会 専門医
平成20年12月 社団法人日本呼吸器学会 指導医

【所属学会】
日本内科学会,日本呼吸器学会,日本癌治療学会,日本肺癌学会,国際世界肺癌会議(The International Association for the Study of Lung Cancer:IASLC),日本癌学会,米国癌学会(American Association for Cancer Research:AACR),米国癌治療学会(American Society of Clinical Oncology: ASCO),日本臨床腫瘍学会,日本血液学会,日本免疫学会,日本感染症学会,日本気管支学会,医学教育学会

【略歴】
昭和58年 4月 岡山大学医学部第2内科入局
平成 4年 1月 岡山大学医学部附属分子細胞医学研究施設助手
平成 4年 4月 岡山大学医学部附属病院助手(第2内科)
平成12年 4月 岡山大学医学部附属病院講師(第2内科)
平成15年10月 岡山大学医学部・歯学部附属病院講師(呼吸器内科)
平成17年 7月 岡山大学大学院医歯薬学総合研究科病態制御科学専攻
       血液・腫瘍・呼吸器内科学分野助教授(現准教授)
平成21年 4月 岡山大学病院副科長(血液・腫瘍内科)(呼吸器・アレルギー内科)
平成23年 5月 岡山大学病院 呼吸器・アレルギー内科 教授
海外渡航歴
平成 5年 7月 1日~平成7年 6月30日 米国ニューヨーク州立大学バッファロー校
病理学教室分子免疫生物学部門(Postdoctoral fellow)として留学

【一言】
進行肺がんの治癒を合言葉に,メディカルスタッフと一丸となり,最高レベルの診療を常に追及しております。

【研究テーマ】
Thoracic Oncology
・Concomitant chemoradiotherapy for locally advanced non-small cell lung cancer
・Chemotherapy and molecular targeted therapy for advanced non-small cell lung cancer
・Activating EGFR gene mutation positive lung cancer
・Chemoprevention for non-small cell lung cancer

【主な業績】

[Concomitant chemoradiotherapy for locally advanced non-small cell lung cancer]

  1. Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N, Hiraki S, Watanabe Y, Bessho A, Eguchi A, Okimoto N, Harita S, Takemoto M, Hiraki Y, Harada M, Tanimoto M for the Okayama Lung Cancer Study Group: Phase I/II Study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer, 89(5):795-802, 2003
  2. Takigawa N, Kiura K, Segawa Y, Watanabe Y, Kamei H, Moritaka T, Shibayama T, Ueoka H, Gemba K, Yonei T, Tabata M, Shinkai T, Hiraki S, Takemoto M, Kanazawa S, Matsuo K, Tanimoto M: Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. Br J Cancer, 95(9):1142-4, 2006
  3. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M: Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol., 28(20):3299-306, 2010
  4. Toyooka S,Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, Miyoshi S, Date H: Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 14(5):565-9, 2012

[Chemotherapy and molecular targeted therapy for advanced non-small cell lung cancer]

  1. Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Hiroshi Ueoka H, Tanimoto M: Triple combination chemotherapy with cisplatin, docetaxel and irinotecan for advanced non—small-cell lung cancer: A phase I/II trial. J Thorrac Oncol.,2(1):44-50, 2007
  2. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M: A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol., 3(4):386-93, 2008
  3. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 20
  4. Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol. 2015;10(3):486-491

 [Chemoprevention for non-small cell lung cancer]

  1. Mimoto J, Kiura K, Matsuo K, Yoshino T, Takata I, Ueoka H, Kataoka M, Harada M:  (-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice. Carcinogenesis, 21(5):915-919, 2000
  2. Hisamoto A, Kondo E,Kiura K, Okada T, Hosokawa S, Mimoto J, Takigawa N, Tabata M, Tanimoto M: Point mutation of K-ras gene in cisplatin-induced lung tumours in A/J mice. Lung Cancer, 58(1);15-20,2007
  3. Kishino D, Kiura K, Takigawa N, Katayama H, Kuyama S, Sato K, Okada T, Ohashi K, Tanimoto M: Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice. Lung Cancer, 65(3):284-9, 2009
  4. Ohashi K, Takigawa N, Osawa M, Ichihara E, Takeda H, Kubo T, Hirano S, Yoshino T, Takata M, Tanimoto M, Kiura K: Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res., 69(17):7088-95, 2009

[Activating EGFR gene mutation positive lung cancer]

  1. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M: Dramatic effect of ZD1839 (‘Iressa’) in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer, 40(1):73-6,2003

  2. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar AF, Shimizu N: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

  3. Ohashi K, Rai K, Fujiwara Y, Osawa M, Hirano S, Takata K, Kondo E, Yoshino T, Takata M, Tanimoto M, Kiura K: Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. Cancer Sci., 99(9):1747-53, 200

  4. Ichihara E,Ohashi K, Takigawa N, OsawaM, Ogino A, TanimotoM,Kiura K: Effects of vandetanib on lung adenocarcinoma cells emerging an acquired EGFR T790M mutation in vivo. Cancer Res., 69(12):5091-8, 2009

  5. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L,de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 109(31):E2127-33, 2012.

  6. Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, Tsukuda K, Takigawa N, Kiura K, Gazdar AF, Lam WL, Miyoshi  S. Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells. Cancer Res. 73(10):3051-61,2013

 [Miscellaneous]

  1. Kiura K, Saijo N:  Can dose-dense chemotherapy improve outcome in patients with betterprognosis small-cell lung cancer?  Nat Clinic Pract Oncol 2(12):610-611.2005

  2. Toyooka S, Kiura K, Mitsudomi T:  EGFR mutation and response of lung cancer to gefitinib. N Engl J Med. 352(20):2136, 2005

  3. Fujiwara Y, Hotta K, Kiura K:  Prophylactic cranial irradiation in small-cell lung cancer. N Engl J Med. 357(19):1977-8, 2008

  4. Ichihara E, Matsuoka J, Kiura K: Early palliative care in non-small-cell lung cancer. N Engl J Med., 363(23):2263, 2010

  5. Hotta K, Nagio T, Matsuo K,Kiura K. Cure- or care-oriented regimen for stage III non-small-cell lung cancer? J Clin Oncol. 29(11):e320,2011

  6. Kiura K. Chemotherapy for lung cancer: still alive! Jpn J Clin Oncol. 2015 [Epub ahead of print] (in press)

戻る

コメントは受け付けていません。